Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAGLA | Q9Y4D2 | 7/20 | 0.64 |
| ▸ | PRKCA | P17252 | 4/20 | 0.60 |
| ▸ | LYPLA1 | O75608 | 4/20 | 0.57 |
| ▸ | LYPLA2 | O95372 | 4/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.56 |
| ▸ | PRKCG | P05129 | 1/20 | 0.56 |
| ▸ | PRKCB | P05771 | 1/20 | 0.56 |
| ▸ | PRKCH | P24723 | 1/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.56 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.50 |
| ▸ | PLA2G6 | O60733 | 2/20 | 0.49 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 5/20 | 0.48 |
| ▸ | PNLIP | P16233 | 2/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714172 | 1.00 | DAGLA (0.64) | DAGLAPRKCALYPLA1LYPLA2PRKD3 | |
| SCHEMBL3447306 | 1.00 | DAGLA (0.64) | DAGLAPRKCALYPLA1LYPLA2PRKD3 | |
| SCHEMBL714173 | 1.00 | DAGLA (0.64) | DAGLAPRKCALYPLA1LYPLA2PRKD3 | |
| SCHEMBL2917942 | 1.00 | DAGLA (0.64) | DAGLAPRKCALYPLA1LYPLA2PRKD3 | |
| SCHEMBL19576215 | 0.91 | DAGLA (0.69) | DAGLAPRKCALYPLA1LYPLA2PRKD3 | |
| SCHEMBL21679661 | 0.91 | DAGLA (0.69) | DAGLAPRKCALYPLA1LYPLA2PRKD3 | |
| SCHEMBL21679665 | 0.91 | DAGLA (0.69) | DAGLAPRKCALYPLA1LYPLA2PRKD3 | |
| SCHEMBL21679653 | 0.91 | DAGLA (0.69) | DAGLAPRKCALYPLA1LYPLA2PRKD3 | |
| SCHEMBL16617217 | 0.91 | DAGLA (0.69) | DAGLAPRKCALYPLA1LYPLA2PRKD3 | |
| SCHEMBL16617219 | 0.91 | DAGLA (0.69) | DAGLAPRKCALYPLA1LYPLA2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751126-B1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | ABBOTT PRODUCTS GMBH (DE) | 2010-09-01 | — | — | EP | disclosed |
| EP-1751126-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-7074822-B2 | Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005080366-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | PNLIP, CEL, LIPE | DAGLA 11/4885PRKCA 262/4885LYPLA1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.